[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353928-105":59,"doc-detail-353928-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","loss-of-prkacb-facilitates-metastasis-of-diffuse-type-gastric-cancer-through-rhoa-signaling-activation","Loss of PRKACB facilitates metastasis of diffuse-type gastric cancer through RhoA signaling activation","","Diffuse-type gastric cancer shows strong invasiveness and poor prognosis, often with peritoneal metastasis, yet the role of protein kinase A catalytic subunit beta (PRKACB) in this process is unclear. This study examines PRKACB expression in diffuse- vs intestinal-type gastric cancer, tests its functions using cell assays and a mouse peritoneal metastasis model, and defines a PRKACB–RhoA regulatory axis via biochemical interaction assays. Results indicate low PRKACB promotes migration, invasion, EMT, and earlier peritoneal metastasis by activating RhoA signaling through phosphorylation at S188, reversing effects with a RhoA inhibitor. Common RhoA mutations weaken PRKACB interaction, further enhancing metastatic potential.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/loss-of-prkacb-facilitates-metastasis-of-diffuse-type-gastric-cancer-through-rhoa-signaling-activation/353928/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/loss-of-prkacb-facilitates-metastasis-of-diffuse-type-gastric-cancer-through-rhoa-signaling-activation/353928.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does PRKACB expression differ between diffuse-type and intestinal-type gastric cancer?","Question",{"text":113,"@type":114},"PRKACB expression is significantly lower in diffuse-type gastric cancer tissues than in intestinal-type gastric cancer and adjacent non-tumor tissues.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What effect does PRKACB have on metastatic behaviors of diffuse-type gastric cancer cells?",{"text":118,"@type":114},"PRKACB knockdown increases migration, invasion, pseudopodia formation, and EMT, while PRKACB overexpression suppresses these activities.",{"name":120,"@type":111,"acceptedAnswer":121},"How is RhoA signaling connected to PRKACB and metastasis?",{"text":122,"@type":114},"PRKACB interacts with RhoA and promotes its phosphorylation at S188, inhibiting RhoA signaling and downstream effectors ROCK1 and FAK; a RhoA inhibitor reverses PRKACB-loss-induced pro-metastatic effects.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353928,1790499192,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nLoss of PRKACB facilitates metastasis of diffuse-type gastric cancer through RhoA signaling activation  \nJie Sun 1,6, Junjie Zhao1,2,6, Xu Yang1,6, Chenyu Tian 1,6, Chengbo Ji1, Jingdong Liu1, Sachiyo Nomura3, Yuanyuan Ruan 1,4 ✉, Xuefei Wang 1,2,5 ✉ and Haojie Li 1,2 ✉  \n© The Author(s) 2026  \n\n|  | Diffuse-type gastric cancer (DGC) is characterized by strong invasiveness and poor prognosis, frequently associated with peritoneal metastasis. Dysregulation of protein kinase A catalytic subunit beta (PRKACB) has been implicated in various cancers, but its role in DGC remains unclear. This study investigates the expression, function, and molecular mechanisms of PRKACB in DGC metastasis. PRKACB expression was analyzed by immunohistochemistry in tissue samples from DGC and intestinal-type gastric cancer (IGC) patients. Functional assays and a mouse peritoneal metastasis model were employed to evaluate the impact of PRKACB on metastasis. The interaction between PRKACB and RhoA was explored using co-immunoprecipitation, GST pull-down assays, and in situ proximity ligation assays. PRKACB expression was signiﬁcantly lower in DGC tissues compared to IGC and adjacent non-tumor tissues. Multivariate Cox regression analysis identiﬁed low PRKACB expression as an independent prognostic factor for poor overall survival. In DGC cell lines, PRKACB knockdown enhanced cell migration, invasion, pseudopodia formation, and epithelialmesenchymal transition (EMT), while PRKACB overexpression suppressed these activities. In vivo experiments demonstrated that PRKACB knockdown promoted earlier onset of peritoneal metastasis. Mechanistically, PRKACB interacted with RhoA and promoted its phosphorylation at S188, thereby inhibiting RhoA signaling and its downstream effectors ROCK1 and FAK. Common RhoA mutations in DGC (V38G and N41K) weakened its interaction with PRKACB, leading to reduced phosphorylation and enhanced metastatic potential. Importantly, RhoA inhibitor treatment reversed the pro-metastatic effects induced by low PRKACB expression. In conclusion, low PRKACB expression promotes DGC metastasis through activation of RhoA signaling, and PRKACB downregulation combined with functional RhoA mutations contributes to the aggressive phenotype of DGC. These ﬁndings provide new insights into DGC progression and suggest that PRKACB may serve as both a prognostic biomarker and a potential therapeutic target for |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| DGC patients. |  |  |\n|  | Cell Death and Disease (2026)17:281; [https://doi.org/10.1038/s41419-026-08553-z](https://doi.org/10.1038/s41419-026-08553-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nGastric cancer is one of the most common malignant tumors in the world today, with over one million new cases estimated annually, ranking it ﬁfth in incidence among all malignancies. Each year, approximately 700,000 people die from gastric cancer, making its mortality rate the fourth highest [1] . China is particularly a high-incidence area for gastric cancer worldwide, with nearly 400,000 new cases and almost 300,000 deaths annually, ranking third in both incidence and mortality rates [2] . The high heterogeneity of gastric cancer is a signiﬁcant factor for its poor prognosis, and the therapeutic outcomes vary among different types of gastric cancer [3] . To better guide clinical diagnosis and treatment, the ﬁeld has proposed various classiﬁcation methods for gastric cancer, among which the Lauren classiﬁcation remains the most commonly used in clinical practice [4] . The principle of the Lauren classiﬁcation is to divide gastric  \ncancer into intestinal, diffuse, and mixed types based on the morphological structure and immunohistochemical staining of tumor tissues under the microscope [5, 6] . A meta-analy","cbCaibEqg2qJn5wT","https://ap.wps.com/l/cbCaibEqg2qJn5wT","pdf",8811448,14,"English","# Introduction\n## PRKACB role in diffuse-type gastric cancer\n## RhoA mutations and diffuse-type gastric cancer\n# Methods and molecular approach\n## PRKACB expression analysis\n## Functional assays and mouse model\n## PRKACB–RhoA interaction experiments","[{\"question\":\"How does PRKACB expression differ between diffuse-type and intestinal-type gastric cancer?\",\"answer\":\"PRKACB expression is significantly lower in diffuse-type gastric cancer tissues than in intestinal-type gastric cancer and adjacent non-tumor tissues.\"},{\"question\":\"What effect does PRKACB have on metastatic behaviors of diffuse-type gastric cancer cells?\",\"answer\":\"PRKACB knockdown increases migration, invasion, pseudopodia formation, and EMT, while PRKACB overexpression suppresses these activities.\"},{\"question\":\"How is RhoA signaling connected to PRKACB and metastasis?\",\"answer\":\"PRKACB interacts with RhoA and promotes its phosphorylation at S188, inhibiting RhoA signaling and downstream effectors ROCK1 and FAK; a RhoA inhibitor reverses PRKACB-loss-induced pro-metastatic effects.\"}]","Loss of PRKACB facilitates metastasis of diffuse-type gastric cancer through RhoA signaling activation | PDF",1790107981,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbb1dc0f7d24c0e7798615f8e10cf9ca.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ff785dc4bf549e213312809a3110410.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ae95309fd9af3d6f8789484ce2fb027.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28f7ca414a083b4cd3a91f942c8e3700.webp",980,1301]